期刊文献+

MyD88+介导卵巢癌紫杉醇化疗抵抗的研究进展 被引量:1

原文传递
导出
摘要 卵巢癌是妇科恶性肿瘤之一,其死亡率居妇科恶性肿瘤的首位。目前卵巢癌的治疗手段主要包括手术和化疗,大部分的卵巢癌患者对紫杉醇联合铂类的化疗敏感,但少数患者对此方案无反应,这可能是导致卵巢癌化疗失败的主要原因之一。大量的研究显示髓样分化因子(MyD88)信号通路介导了肿瘤形成并与肿瘤化疗抵抗有关,许多学者对其进行深入研究,发现MyD88可能通过不同的信号传导通路促进促炎症细胞因子、凋亡抑制蛋白Survivin、血管内皮生长因子的表达等介导了卵巢癌对紫杉醇抵抗。本文就MyD88的生物学特性及MyD88信号通路与卵巢癌紫杉醇抵抗的研究进展进行综述。
出处 《肿瘤预防与治疗》 2014年第1期48-51,共4页 Journal of Cancer Control And Treatment
  • 相关文献

参考文献24

  • 1Silasi D A,Alvero A B,Illuzzi J. Cancer Issue:MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer[J].Yale Journal of Biology and Medicine,2006,(3-4):153-163.
  • 2Burns K,Martinon F,Esslinger C. MyD88,an adapter protein involved in interleukin-1 signaling[J].Journal of Biological Chemistry,1998,(20):12203-12209.
  • 3朱熠,黄建鸣,张国楠.TLR4/MyD88信号通路介导卵巢癌紫杉醇耐药机制的研究进展[J].中华妇产科杂志,2011,46(11):873-876. 被引量:6
  • 4Palsson-McDermott EM,Doyle SL,McGettrick AF. TAG,a splice variant of the adaptor TRAM,negatively regulates the adaptor MyD88-independent TLR4 pathway[J].Nature Immunology,2009,(06):579-586.
  • 5Wang AC,Su QB,Wu FX. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells[J].European Journal of Clinical Investigation,2009,(02):157-164.
  • 6Eiró N,Vizoso FJ. Inflammation and cancer[J].World Journal of Gastrointestinal Surgery,2012,(03):62-72.
  • 7Karin M,Greten FR. NF-κB:linking inflammation and immunity to cancer development and progression[J].Nature reviews Immunology,2005,(10):749-759.
  • 8Pikarsky E,Porat RM,Stein I. NF-κB functions as a tumour promoter in inflammation-associated cancer[J].NATURE,2004,(7007):461-466.
  • 9于月红,钱雷,陈玮.结直肠癌组织Toll样受体4和髓系分化蛋白88mRNA检测[J].海南医学,2011,22(12):9-11. 被引量:3
  • 10Swann JB,Vesely MD,Silva A. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis[J].Proceedings of the National Academy of Sciences of the United States of America,2008,(02):652-656.

二级参考文献39

  • 1Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity [J]. Cell, 2006, 124: 783-801.
  • 2Jemal A, Siegel R, Ward E, et al .Cancer statistics [J]. CA Cancer J Clin, 2009, 59: 225-249.
  • 3Wolpin BM, Mayer ILl Systemic treatment of colorectal cancer[J]. Gastroenterology, 2008, 134: 1296-1310.
  • 4Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword [J]. Oncogene, 2008, 27: 218-224.
  • 5Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer [J]. Nat Rev Cancer, 2009, 9: 57-63.
  • 6Bohnhorst J, Rasmussen T, Moen SH. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia:Official Journal of the Leukemia Society of America [J]. Leukemia Research Fund, UK, 2006, 6: 228-234.
  • 7Takeda K, Kaisho T, Akira S. Toll like receptors [J]. Aunu Annu Rev Immunol, 2003, 21: 335- 376.
  • 8Lee S J, Lira KT. UDN glycoprotein regulates activities of activator protein-1, and nuclear factor-kB stimulated by reactive oxygen radicals in lipopolysaecharide-stimulated HCT-I16 cells [J]. Cancer Lett, 2007, 254: 274- 287.
  • 9He W, Liu Q, Wang L, et al .TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive eytokines and apoptosis [J]. Mol Immunol, 2007, 44(11): 2850-2859.
  • 10Earl TM, Nicoud IB, Pierce JM, et al.Silencing of TLR4 decreases liver tumor burden in a murine model of coloreetal metastasis and hepatic steatosis [J]. Ann Surg Oncol, 2009, 16: 1043-1050.

共引文献7

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部